Invariant Natural Killer T Cells in Asthma and Chronic Obstructive Pulmonary Disease A sthma is characterized by a speci fic form of airway inflammation that is believed to be orchestrated by CD4+ helper T cells of the type 2 (Th2) phenotype in response to allergens presented by mucosal dendritic cells. 1 Th2 CD4+ T cells release the cytokines interleukin-4, interleukin-5, and interleukin-13, which play key roles in airway inflammation and remodeling. 2 The Th2 CD4+ T cells have been generally accepted to be class II major-histocompatibility-complex (MHC)-restricted cells. 3 This notion has recently been challenged in a study by Akbari and colleagues, 4 which found that about 60% of the CD4+ T cells in the airways of persons with asthma, but not those in the airways of healthy persons, are invariant natural killer T cells, a subgroup of immunoregulatory T lymphocytes restricted by the antigen-presenting molecule CD1d. Their study also showed that bronchoalveolar-lavage cells challenged with α-galactosylceramide, a potent stimulus for invariant natural killer T cells, produce Th2 cytokines, implying a pivotal role in allergic airway inflammation. 4 There have been two other reports of elevated levels of invariant natural killer T cells in the airways of persons with asthma, 5,6 although both of them reported lower cell counts than those reported by Akbari et al. More recently, the findings of Akbari et al. have been challenged by Thomas et al., 7 who found low numbers of invariant natural killer T cells (0.4 to 2.1%) in persons with asthma not treated with corticosteroids.
We further investigated the role of invariant natural killer T cells in airway disease to determine whether these cells are not only a feature of moderately severe asthma requiring treatment with inhaled corticosteroids, as reported by Akbari et al., 4 but are also abundant in mild asthma and chronic obstructive pulmonary disease (COPD). We obtained samples from the airways of subjects with asthma, subjects with COPD, and healthy controls, using bronchoalveolar lavage, sputum induction, and bronchial biopsy. We examined the specimens for invariant natural killer T cells using a combination of flow cytometry and real-time polymerase-chain-reaction (PCR) analysis of gene expression for the Vα24 and Vβ11 domains of the T-cell receptor that characterize invariant natural killer T cells. [8] [9] [10] Me thods
Study Population
The study was approved by the ethics committee of the Southampton University Hospitals Trust, and all subjects provided written informed consent. Twenty-four subjects with asthma (8 with mild asthma not treated with inhaled corticosteroids, and 16 with moderately severe asthma treated with inhaled corticosteroids), 10 subjects with COPD meeting established diagnostic criteria, 11, 12 and 12 controls were studied (Table E1 in the Supplementary Appendix, available with the full text of this article at www.nejm.org). All subjects with asthma had had stable symptoms within at least 6 weeks before enrollment. Of these, 22 subjects had atopic asthma, as shown by a positive skinprick test for a panel of common allergens, and all had bronchial hyperresponsiveness, as demonstrated by the provocative concentration of histamine causing a 20% fall in the forced expiratory volume in 1 second of less than 8 mg per milliliter or peak flow variability of more than 20%. Five of the 10 subjects with COPD were studied during an infectious exacerbation to determine whether there was any contribution by infection to the involvement of invariant natural killer T cells, given the well-established role of these T cells in innate immunity. 8 All subjects with COPD had disease ranging from stage 0 to stage 3, according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease, 12 and were either current or former heavy smokers; none had a history of asthma or other lung diseases. Exacerbation was defined on clinical and radiologic grounds, according to the guidelines of the British Thoracic Society. 13
Collection and Preparation of the Samples
Sputum induction was performed according to the recommendations of the European Respiratory Society, and the samples were immediately processed with the use of dithioerythritol to separate cells from the fluid phase of sputum. 14 Cell aliquots were immediately processed for flow-cytometric analysis.
Of the 24 subjects with asthma, 18 (5 with mild asthma and 13 with moderately severe asthma) underwent fiberoptic bronchoscopy for either bron- 
Phenotypic Analysis
Cell-surface expression of the invariant natural killer T-cell receptor was detected on flow cytometry with the use of the seven-color FACSAria cell sorter (BD Biosciences) by applying the following monoclonal antibodies in combination with anti-CD3 and anti-CD4 monoclonal antibodies (BD Biosciences): R-phycoerythrin-conjugated anti-Vα24 monoclonal antibody, fluorescein isothiocyanate (FITC)-conjugated anti-Vβ11 monoclonal antibody (Immunotech), R-phycoerythrin-conjugated CD1d tetramers loaded with α-galactosylceramide and R-phycoerythrin-conjugated 6B11 monoclonal antibody directed against the complementarity-determining-region 3 of the Vα24-Jα18 T-cell receptor of invariant natural killer T cells (BD Biosciences). Nonspecific binding of antibodies to Fcγ receptors was blocked with 2 mg per milliliter of polyclonal human IgG (Sigma). Initially, cell doublets, which could contain adherent cells (e.g., macrophages) and dead cells and thus could bind antibodies nonspecifically, were excluded on gating with the use of pulse width and area ( We used oligonucleotide probes for real-time PCR of the genes encoding Vα24 (TRAV10, according to the International ImMunoGeneTics [IMGT] information system nomenclature) and Vβ11 (TRBV25-1) as well as probes to detect expression of the constant chain of the T-cell receptor (TRBC2 gene) (PrimerDesign). The primers were aligned with other variable regions to confirm that there was no significant homology with any other variable region (for primer detection kits, see the Supplementary Appendix).
R e sult s

Bronchoalveolar-Lavage Analysis
The initial flow-cytometric analyses for invariant natural killer T cells were performed on samples of bronchoalveolar-lavage fluid obtained from subjects with asthma, permitting direct comparisons with previous studies of invariant natural killer T cells in asthma 4 and sarcoidosis. 16 The analysis of samples obtained from 11 subjects with asthma (3 with mild asthma and 8 with moderately severe asthma) using the Vα24 and Vβ11 monoclonal antibodies, which detected all invariant natural killer T cells, [8] [9] [10] showed that invariant natural killer T cells constituted less than 2% of the CD3+ cells and less than 1.5% of the CD3+CD4+ cells (Table 1) . Similar counts were obtained when we used CD1d tetramers loaded with α-galactosylceramide 17 or the 6B11 monoclonal antibody (Fig.  1 and 2 and Table 2 ). Routine total and differential cell counts of bronchoalveolar-lavage cells are shown in Table 3 .
To create a positive control for detecting invariant natural killer T cells in bronchoalveolar-lavage cells with the use of flow cytometry, we "spiked" a bronchoalveolar-lavage sample with cells from the invariant natural killer T-cell clone (for validation of the cell clone, see Fig. E7 in the Supplementary Appendix). Using the gating principles outlined in Figure 1 and Figure 2 , we detected invariant natural killer T cells in the spiked sample, with the relative numbers (percentages of total CD3+ T cells) corresponding to the numbers of added invariant natural killer T cells (Fig. 3) . This confirmed the ability of both the antibodies used and the gating strategy to detect invariant natural killer T cells. Further phenotyping of CD3+ CD4+ cells showed these cells to be predominantly activated memory T cells expressing CD69 and CD45RO ( The next analysis for invariant natural killer T cells was performed on airway cells obtained by sputum induction, 14 which permitted us to study a larger number of subjects than did the analysis of bronchoalveolar-lavage fluid. This method samples predominantly proximal airways, the sites of significant inflammation in asthma, which could, conceivably, be different from the distal airways sampled by bronchoalveolar lavage. We also used induced sputum to study controls and subjects with stable COPD and COPD during an infectious exacerbation. In preliminary experiments (Fig. E9 in the Supplementary Appendix), the reducing agent dithioerythritol, which is used to solubilize sputum and thereby make its analysis possible, was shown Fig. 1 and 2 ) and with the use of anti-CD3 antibody. NA denotes not analyzed, and COPD chronic obstructive pulmonary disease. † There were 16 subjects with moderately severe asthma, 8 with mild asthma, 12 controls, 5 subjects with COPD with acute exacerbations, and 5 with stable COPD. Some subjects underwent sampling by more than one method. not to affect the expression of the invariant natural killer T-cell receptor on human invariant natural killer T-cell clones.
Between 0.2 and 14.3% of the sputum cells were CD3+, of which 27 to 91% were CD4+. As in the bronchoalveolar-lavage analysis, very few invariant natural killer T cells were identified in samples from subjects with mild asthma (0 to 0.1% of all CD3+CD4+ cells) and those with moderately severe asthma (0 to 1.3% of all CD3+CD4+ cells) ( Fig. 2 and Table 1 ). Similarly low counts of invariant natural killer T cells were found in sputum from controls and subjects with COPD (Table  1) . Cell counts in sputum from subjects with mild asthma and those with moderately severe asthma were grouped for statistical comparison (with the use of the Mann-Whitney U test) with cell counts in subjects with COPD and controls. No significant differences were found between the groups (P>0.30 for the comparison between subjects with asthma Cells were stained with the use of the CD1d tetramer loaded with α-galactosylceramide (αGal) and the 6B11 antibody for the complementarity-determining-region 3 of the Vα24-Jα18 domain of the T-cell receptor, in addition to standard use of R-phycoerythrin-conjugated anti-Vα24 antibody and fluorescein isothiocyanate (FITC)-conjugated anti-Vβ11 antibody. The analysis was based on gating of CD3+ T cells (Panel A). R-phycoerythrin-conjugated antibody (6B11) and R-phycoerythrin-conjugated CD1d tetramers loaded with αGal did not detect invariant natural killer (iNK) T cells in the bronchoalveolar-lavage (BAL) sample (Panel B). As a positive control for detection of iNK T cells, the sample was "spiked" with cells from the iNK T-cell clone (Panel C). With the use of the gating principles ( Fig. 1) , iNK T cells were detected in the spiked sample, confirming that both the antibodies and the gating strategy were working (Panel C). and controls, and P>0.40 for the comparison between subjects with stable or exacerbated COPD and controls).
Bronchial-Biopsy Analysis
Because cells in mucosal tissue could differ from luminal cells, the final flow-cytometric analysis of invariant natural killer T cells was conducted on cells from bronchial-biopsy specimens with the use of enzymatic dispersion with collagenase. We used flow cytometry on dispersed bronchial biopsy-tissue cells to make possible a direct comparison with cells obtained on bronchoalveolar lavage and sputum induction. In addition, flow cytometry permitted the elimination of nonspecifically stained monocytes and macrophages. Because the CD4 epitope on T cells is cleaved during treatment with collagenase, 18 the analysis was restricted to CD3+ T cells. In preliminary experiments (Fig. E9 in the Supplementary Appendix), collagenase treatment was shown not to affect the detection of the Vα24 and Vβ11 T-cell receptors on invariant natural killer T-cell clones. Between 0.2 and 7.6% of all cells obtained on biopsy were CD3+ T cells. Consistent with the findings in samples of bronchoalveolarlavage cells and sputum, counts of invariant natural killer T cells ranged from 0 to 1.7% of CD3+ T cells (Fig. 3 and Table 1 ).
Expression of Messenger RNA for T-Cell Receptors Vα24 and Vβ11
To corroborate the results obtained on flow cytometry with the use of a different method, we performed quantitative (real-time) PCR to detect the messenger RNA (mRNA) for the genes of the T-cell-receptor family, Vα24 (TRAV10) and Vβ11 (TRVB25-1), on bronchoalveolar-lavage cells obtained from eight subjects with asthma and sputum cells obtained from four subjects with asthma, four with COPD, and seven controls. Amplified expression values for mRNA were normalized against signals obtained for the constant chain of the T-cell receptor encoding mRNA. The signal used to normalize the results was lower in the bronchoalveolar-lavage cells than in the invariant natural killer T-cell clones; titration experiments with the use of 10-fold serial dilution of the natural killer T-cell clones showed that the PCR detection kits for the T-cell receptors Vα24 and Vβ11 and the constant chain were extremely sensitive, * Total cell counts in bronchoalveolar-lavage samples ranged from 0.8×10 6 per milliliter to 22.6×10 6 per milliliter. Differential cell counts were performed manually on 400 cells with the use of cytospin preparation of bronchoalveolarlavage fluid and the Rapi-Diff II stain pack (Bios-Europe). Differential cell counts were not analyzed in some subjects, because whole samples were used for extensive validation of flow cytometry and real-time PCR. NA denotes not analyzed. Of the CD3+CD4+ T cells from sputum obtained from a subject with asthma, a control, and a subject with COPD and treated with dithioerythritol, 0 to 1.3% of the T cells stained for both the Vα24 and Vβ11 domains and were therefore identified as invariant natural killer T cells (Panel A). For the analysis of bronchial mucosal CD3+ T cells obtained from a representative subject with moderately severe asthma, bronchial-biopsy specimens were treated with collagenase to disperse cells and the cells were then incubated with antibodies for CD3, Vα24, and Vβ11 (Panel B). Dead cells were excluded, and positive gating was performed for mononuclear cells and CD3+ cells. Dead cells appear as red, and live cells appear as green. There was no nonspecific staining, as shown by the IgG1 isotype control antibody, but there was also no positive staining for invariant natural killer T cells. Staining with CD1d tetramers loaded with α-galactosylceramide (αGal) and the 6B11 monoclonal antibody confirmed the result. Specimens were obtained from two subjects with mild asthma, and the results of staining by antibodies for Vα24 and Vβ11 are shown. FITC denotes fluorescein isothiocyanate, PI propidium iodide, FSC forward-scatter characteristics, and SSC side-scatter characteristics. detecting as few as 10 cells (Fig. E10 in the Supplementary Appendix). Strong signals for both the constant chain of the T-cell receptor and the mRNA of the individual invariant natural killer T-cell-receptor domains Vα24 and Vβ11 were measured in positive control experiments with the use of complementary DNA of invariant natural killer T-cell clones as a template. In contrast, bronchoalveolar-lavage cells from subjects with asthma did not express mRNA for either the Vα24 or Vβ11 gene, even though mRNA for the constant chain of the T-cell receptor was readily detected. This finding confirmed the presence of T cells in the samples, but it also ruled out the possibility that invariant natural killer T cells were numerous in bronchoalveolarlavage fluid from subjects with asthma (Fig. 3) . Similar findings were observed with the use of sputum cells (Table E2 in the Supplementary Appendix).
Copyright
In further experiments, real-time PCR for mRNA expression of the invariant natural killer T-cell receptor (Vβ11) relative to the expression of the constant chain of the T-cell receptor was performed on peripheral blood T cells that had been "spiked" with invariant natural killer T-cell clones so that the samples contained 100%, 60%, and 2% of invariant natural killer T cells. This method generated a "standard curve" for the expression of the Vβ11 gene (TRVB25-1) relative to the gene encoding the constant chain of the T-cell receptor. The result established that the proportion of T cells expressing T-cell receptor Vβ11-encoding mRNA was less than 2% in all samples obtained by bronchoalveolar lavage and sputum induction (Fig. 4) .
Dis cus sion
Unlike some previous reports, our data show that invariant natural killer T cells are a minority cell population in human lungs of subjects with asthma, constituting less than 2% of the T cells in both the airway lumen (in samples of sputum and bronchoalveolar-lavage fluid) and mucosa (in samples obtained on bronchial biopsy). Moreover, the frequency of invariant natural killer T cells in samples obtained from subjects with asthma did not differ significantly from the frequency in samples obtained from healthy controls or from subjects with stable COPD or COPD during exacerbation.
Invariant natural killer T cells are characterized on the basis of their dual staining for the T-cellreceptor domains Vα24 and Vβ11, positive staining with the use of CD1d tetramers loaded with α-galactosylceramide, or both. [8] [9] [10] In this study, we used both criteria in addition to using the 6B11 antibody directed against the invariant Vα24-Jα18 region of the invariant natural killer T-cell receptor. Our findings of low counts of invariant natural killer T cells were supported by our inability to detect mRNA for either T-cell-receptor gene Vα24 or Vβ11 in samples of bronchoalveolar-lavage fluid or sputum from subjects with asthma (Fig. 4 , and Table E2 in the Supplementary Appendix). In addition, we were unable to demonstrate the production of Th2 cytokines by bronchoalveolar-lavage cells from subjects with asthma stimulated with α-galactosylceramide (Supplementary Appendix), the specific stimulus for invariant natural killer T cells. In support of our findings, Thomas et al. found similarly low numbers of invariant natural killer T cells in subjects with asthma not receiving corticosteroids. 7 Our review of two studies claiming that the numbers of invariant natural killer T cells were elevated in asthma showed that the strict criteria for detecting invariant natural killer T cells were not met in these studies. 5, 19 Although another study 6 suggested that the numbers of invariant natural killer T cells were slightly elevated in children with severe asthma, the numbers were within the same range as those in our study.
Flow-cytometric analysis of airway T cells is fraught with difficulty because of large numbers of autofluorescent macrophages and cell debris. 20, 21 For this reason, we have excluded dead cells and cell doublets (Fig. 1) . Also, we used allophycocyanin as the fluorescent dye to avoid autofluorescence. Alveolar macrophages can nonspecifically bind both antibodies and CD1d tetramers loaded with α-galactosylceramide used to identify invariant natural killer T cells, giving rise to further false positive results on staining. We show that the major fraction of all CD4+Vα24+ cells are identifiable in the nonlymphocyte portion of the forward-and side-scatter plot (Fig. E4 in the Supplementary Appendix) (a finding that can be explained by the presence of CD4 on macrophages) if these cells are not excluded by their typical forward-and sidescatter properties. In contrast, when all measures are used to avoid nonspecific staining and when combining anti-CD3 and anti-CD4 antibodies ( lar problems related to nonspecific binding are encountered with both anti-CD3 antibodies and CD1d tetramers loaded with α-galactosylceramide ( Fig. E5 and E6 in the Supplementary Appendix). Thomas et al. have proposed that the use of the 6B11 antibody, which recognizes the invariant complementarity-determining-region 3 loop of the invariant natural killer T-cell receptor, without using anti-Vα24 or anti-Vβ11 antibodies is inappropriate. 7 Therefore, we used a more comprehensive panel of antibodies, including 6B11 monoclonal antibody, anti-Vα24 monoclonal antibody, and anti-Vβ11 monoclonal antibody, as well as CD1d tetramers loaded with the invariant natural killer T ligand α-galactosylceramide, and all these consistently showed low counts of invariant natural killer T cells in all analyzed samples. In summary, in contrast to the report by Akbari et al., 4 our study found very few invariant natural killer T cells in the airways of subjects with either mild or moderately severe asthma, subjects with stable COPD or COPD during an exacerbation, and healthy controls. This finding strongly questions the significance of invariant natural killer T cells in the pathogenesis of asthma. Our data suggest that therapeutic strategies in asthma should therefore continue to be focused on class II MHCrestricted T cells rather than on invariant natural killer T cells.
